Extending in vivo half-life of therapeutic proteins (L-11944) . : NR16-182/2017E-PDF

“Post-translational modifications of therapeutic proteins are commonly made to improve their circulating half-life, thereby enhancing their efficiency. Numerous strategies have been employed towards this end, including covalent modification, such as through PEGylation, the chemical addition of chains of polyethylene glycol (PEG) to therapeutic proteins. However, PEGylation relies on chemical conjugation of PEG chains to free amino groups or engineered cysteine residues on the protein, which can lead to heterogeneously-modified proteins whose activity can be adversely affected. To address this, the NRC has developed a site-specific, two-step in vitro modification process whereby polysialic acid (PSA) is enzymatically added to existing glycans, resulting in proteins with greater stability, solubility and circulating half-life”--Highlights.

Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.847765&sl=1

• Format MARC XML
• Format MARC HTML

Demander des formats alternatifs